Skip to content
About SpectraCure
Strategy
Market Overview
Clinical Studies
The Product
Method
Patent
Newsroom
Press releases
News
Investor letter
Media bank
Investor
Financial reports
Financial calendar
Owners
The share
Certified adviser
Prospectus
Governance
Governance report
Articles of Association
General meetings
Nomination committee
Board
Auditor
Management
Contact
Career
About SpectraCure
Strategy
Market Overview
Clinical Studies
The Product
Method
Patent
Newsroom
Press releases
News
Investor letter
Media bank
Investor
Financial reports
Financial calendar
Owners
The share
Certified adviser
Prospectus
Governance
Governance report
Articles of Association
General meetings
Nomination committee
Board
Auditor
Management
Contact
Career
SV
EN
Press releases archive
Start
/
Newsroom
/
Press releases archive
Press releases
News
Investor letter
Media bank
Press releases
News
Investor letter
Media bank
2024
2023
2022
2021
2020
2019
2018
2017
2024
2024-02-23 09:30
SpectraCure takes the next step in the work with the new clinical study
Regulatory
2024-01-23 11:45
A well-accomplished annual audit in accordance with ISO 13485:2016
2023
2023-12-19 08:30
Expert group comments on results of ongoing study
Regulatory
MAR
2023-11-16 15:30
SpectraCure has decided to seek approval for a clinical study of primary prostate cancer
Regulatory
MAR
2023-10-06 14:30
SpectraCure strengthens presence among urologists
2023-06-27 11:30
SpectraCure has been awarded an additional EU grant for industrialisation of the company’s treatment system Q-PRO®
Regulatory
2023-02-23 10:00
Approval for clinical study at Skåne University Hospital
Regulatory
2023-02-02 14:40
Positive feedback from treatment with SpectraCure’s system Q-PRO® in New York
Regulatory
2022
2022-12-14 10:15
Masoud Khayyami has been appointed as interim CEO of SpectraCure
Regulatory
2022-12-07 11:00
SpectraCure signs Letter of Intent with Cheplapharm
Regulatory
MAR
2022-11-25 11:10
First treatment with Q-PRO[®] and integrated image management technology
Regulatory
2022-11-21 13:00
Skåne University Hospital in Malmö is included in the clinical trial for treatment of recurrent prostate cancer
Regulatory
2022-11-03 09:00
SpectraCure has registered the trademark Q-PRO[®]
Regulatory
2022-09-19 12:00
SpectraCure’s new treatment system has been approved in the UK for use in clinical trials
Regulatory
2022-08-30 11:00
Patent regarding the new generation of treatment systems approved in Europe
Regulatory
2022-07-18 19:10
SpectraCure’s CEO is leaving the company
Regulatory
MAR
2022-06-20 12:00
Software for improved imaging technology is approved for use in clinical study in the US
Regulatory
2022-06-07 14:15
SpectraCure has been approved a grant from EU of € 125,000
Regulatory
2022-06-03 11:30
Patent approved in Europe
Regulatory
2022-05-16 11:00
A new Board has been installed at SpectraCure
2021
2021-10-13 16:00
Status update on clinical trial for the treatment of relapsed prostate cancer patients
Regulatory
MAR
2021-07-12 13:00
Investor Letter July 2021
2021-05-18 15:45
SpectraCure AB publishes Quarterly Report 1, 2021
Regulatory
MAR
2021-04-15 14:00
The Nomination Committee’s proposal for election of board members in SpectraCure AB
Regulatory
2021-03-15 08:45
Johan Folkunger appointed new CEO of SpectraCure AB
Regulatory
MAR
2021-03-05 08:30
Status update regarding clinical studies for the treatment of patients with recurrent prostate cancer
Regulatory
MAR
2020
2020-11-27 17:30
Positive discussions at SpectraCure’s Investigator Meeting
Regulatory
2020-11-12 12:30
Interim Report Q3, 2020
Regulatory
MAR
2020-09-16 13:48
Looking for excellent, highly-skilled education and training in the vibrant field of Biophotonics? Apply now!
2020-08-25 08:30
Interim Report Q2, 2020
Regulatory
MAR
2020-06-26 13:30
SpectraCure raises approximately SEK 140 million through a fully subscribed rights issue
Regulatory
MAR
2020-06-18 15:30
Wider range of prospective patients in the UK, Canada and the US for continued clinical study
Regulatory
2020-06-16 18:19
A future alternative to hormonal treatment for prostate cancer
Regulatory
2020-06-01 19:54
Subscription period postponed for the rights issue. Other conditions remain unchanged
Regulatory
2020-06-01 14:12
Patent application submitted to protect new technology
Regulatory
2020-06-01 13:45
SpectraCure’s MSEK 140 rights issue of units is fully guaranteed
Regulatory
MAR
2020-05-28 14:45
SpectraCure AB Quarterly Report (1 Jan to 31 March) 2020
Regulatory
MAR
2020-04-07 10:00
Patent application enters PCT phase, SpectraCure ensures development and work
Regulatory
MAR
2020-03-16 13:15
New study underway in the US and approval from the Food and Drug Administration (FDA)
Regulatory
MAR
2020-03-12 11:35
The meeting between SpectraCure and Memorial Sloan Kettering Cancer Center in New York, USA takes place tomorrow, March 13 2020
Regulatory
2020-03-06 11:30
Agreement reached between SpectraCure and one more hospital – Memorial Sloan Kettering Cancer Center i n New York
Regulatory
MAR
2020-02-25 12:00
Year End Report 2019
Regulatory
MAR
2020-02-24 11:30
Reinforcements in SpectraCure’s organization
Regulatory
2020-01-17 14:50
A welcome addition to support our ongoing product development. SpectraCure receives research contribution from the EU.
Regulatory
2019
2019-12-04 09:15
Exercise rate of 98.8 percent for SpectraCure’s warrants (TO3)
Regulatory
MAR
2019-11-26 15:56
Last day of trading of SPEC TO3 subscription warrants tomorrow, Nov. 27
Regulatory
2019-11-13 14:20
SpectraCure´s main owner subscribes in full for his share
Regulatory
2019-11-12 14:00
SpectraCure AB Quarterly Report (1 July to 30 September) 2019
Regulatory
MAR
2019-10-28 11:10
The FDA’s initiative can provide faster market access for SpectraCure
Regulatory
MAR
2019-10-16 11:02
SpectraCure at Stora Aktiedagen in Gothenburg
Regulatory
2019-10-07 10:26
SpectraCure to the Premier Segment of First North Growth Market
Regulatory
2019-09-24 16:27
Correction: Improved treatment technology in the fight against prostate cancer is used directly in an ongoing clinical trial
Regulatory
MAR
2019-09-24 14:35
Improved treatment technology in the fight against prostate cancer is used directly in an ongoing clinical trial
Regulatory
MAR
2019-09-16 10:15
SpectraCure presentations at investor meetings this fall
Regulatory
2019-08-22 10:40
SpectraCure strengthens the organization with a PR Manager
Regulatory
2019-08-21 14:00
SpectraCure AB Quarterly report (1 April to 30 June) 2019
Regulatory
MAR
2019-08-14 11:10
SpectraCures new generation P18
Regulatory
2019-07-08 09:45
Great attention for SpectraCure in Boston
Regulatory
2019-07-02 15:15
SpectraCure reports positive results from the company’s clinical phase 1-study
Regulatory
MAR
2019-06-10 13:55
SpectraCure presents results from Phase 1 study
Regulatory
2019-05-23 12:42
Preliminary results from SpectraCure’s prostate treatments
Regulatory
MAR
2019-04-10 10:46
New patient treatment, phase 2 initiated
Regulatory
MAR
2019-04-05 13:53
SpectraCure files for a new patent
Regulatory
MAR
2019-03-29 15:49
Status report for phase 2 study
Regulatory
2019-03-01 08:37
Final preparation for Phase 2 – SpectraCure extends contract with hospital in London
Regulatory
2019-02-15 12:00
SpectraCure AB Year-end report 1 January – 31 December 2018
Regulatory
MAR
2019-02-15 09:22
More results from Phase 1 study
Regulatory
2019-01-28 14:02
Results from clinical study for patient 9 and 10
Regulatory
MAR
2018
2018-12-21 10:36
SpectraCure receives prestigious grant from the Eurostars program
Regulatory
MAR
2018-12-17 14:57
SpectraCure one step closer to Phase 2 after successful treatment effect in recent patients
2018-05-04 09:10
Continued patient treatments in clinical trial
Regulatory
2018-04-23 10:03
Agreement signed with the University of Pennsylvania Hospital for Clinical Study on Prostate Cancer Treatment
Regulatory
MAR
2018-04-10 14:27
The ethics committee in London gives approval to start clinical study
Regulatory
MAR
2018-03-23 08:58
Additional results from clinical phase 1 study
Regulatory
MAR
2018-03-07 15:30
Clinical results from SpectraCure’s fourth patient treatment
Regulatory
MAR
2018-02-28 14:08
British Medicines Agency MHRA approves clinical study
Regulatory
MAR
2018-02-23 09:01
New patient treatment in the clinical phase 1 study
Regulatory
2018-02-15 13:02
SpectraCure initiates process for change of listing
Regulatory
MAR
2018-02-14 08:00
SpectraCure at G&W Capital Market Day, 2018
2018-02-07 08:16
Scientific and technical meetings at SPIE Photonics West
2018-01-18 14:07
SpectraCure to participate in a large research programme funded by Knut and Alice Wallenberg Foundation
Regulatory
MAR
2018-01-17 08:45
Patent for treatment consumable approved in Canada
2017
2017-11-22 14:47
Results and strategies of the clinical studies were discussed with the responsible physician
Regulatory
2017-11-13 15:35
PSA-values from clinical prostate trial mentioned on SpectraCure presentation at ”Stora Aktiedagen” in Stockholm
Regulatory
2017-11-13 08:30
SpectraCure presents the company and the progress on their current clinical trial
Regulatory
2017-11-08 15:49
The CEO of SpectraCure increases his shareholding through MK Capital
2017-10-18 09:54
Imaging material from clinical Phase 1 study
Regulatory
2017-10-03 14:07
Concept study for next generation product completed
Regulatory
2017-09-28 12:29
More preliminary results from the clinical Phase 1 study
Regulatory
2017-09-06 09:31
Positive preliminary results from the clinical Phase 1 study are presented at a scientific conference
Regulatory
MAR
2017-08-25 08:46
Full drug dose achieved in prostate trial
Regulatory
MAR
2017-07-05 08:45
EU Grant awarded through Vinnova
Regulatory
MAR
2017-06-26 09:47
An additional patient has been treated in Toronto, Canada
Regulatory
MAR
2017-06-01 10:36
Patent for dose control approved in Canada
Regulatory
MAR
2017-05-23 15:15
Communiqué from the Annual General Meeting 2017
Regulatory
2017-05-18 11:58
SpectraCure initiates a joint project with German company MedCom GmbH
Regulatory
MAR
2017-04-24 09:58
Patient treatments started in clinical Phase 1 study
Regulatory
2017-04-21 08:17
Notice of annual general Meeting of SpectraCure AB (publ)
Regulatory
2017-01-24 13:30
The first day of trading with warrants of series TO2 is estimated at 27 January 2017
Regulatory
2017-01-18 17:03
SpectraCure decides on Set-off Issue
Regulatory
